877.669.4367 
Checkout
Corporate Information
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition.
HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations.
Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs including tinctures, proprietary FDA Drug Listed Over The Counter (OTC) Topicals, Doctor/Practitioner Lines and more.
With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™️ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com.
Learn About our Upcoming IPO
Please complete the form below to receive the Company’s Investor Presentation and Prospectus. If you have any questions, please call us at 416-803-5638 or email us at [email protected].
Investment Highlights
COMPLIANCE DRIVEN
- HempFusion’s uncompromising approach to regulatory compliance has positioned the Company for potential entry into major retail markets that may be unavailable to other CBD companies, this includes: Large food, drug and mass retail chains (“Food/Drug/Mass” or “Big Box”), Doctor/Practitioner, Convenience and more
- The Company has multiple certifications, and executive memberships that take anywhere from 18-24 months to replicate in addition to a significant capital investment
- HempFusion is a board member of the US Hemp Roundtable, a coalition of leading companies committed to advancing safe hemp and CBD products
- Ola Lessard, HempFusion’s CMO, is the President of the US Hemp Roundtable
MULTIPLE REVENUE DRIVERS
- FDA Drug Listed OTC Topicals allow access to the largest channel by dollar value; Food/Drug/Mass (Big Box)
- Convenience Channel, providing access to significant new sales & distribution opportunities
- Products are currently sold in 4,000+ retail locations across 50 states including Sprouts, Vitamin Shoppe, and Fresh Thyme Market
- Revenue opportunities from 5 robust channels; Natural, Ecommerce, Big Box, Convenience and Doctor Practitioner
PROPRIETARY CBD PRODUCT PORTFOLIO
- The Company’s diverse product portfolio includes 46 products on the market from tinctures to proprietary FDA Drug Listed Over-The-Counter (“OTC”) Topicals to Doctor/Practitioner Lines and Probulin’s scientifically validated delivery systems
- HempFusion Wellness Inc.’s family of brands includes: HempFusion, Probulin Probiotics, Biome Research, and HF Labs
RESEARCH & DEVELOPMENT
- 30 products under development including OTC Drug Listed Ingestibles and additional topicals
- planned launch of plant-based CBD organic gummies
- Human Safety Study (Liver Toxicology 2020) is in progress (1)
- Self GRAS Affirmation (October 2020 publishing) & NOAEL Safety Review completed for all topicals
BOLSTERED C-SUITE AND BOARD OF DIRECTORS WITH PROVEN AND EXPERIENCED EXECUTIVES
- Extensive leadership, public market, finance, legal, CPG and M&A experience are crucial assets in driving the Company’s business plan forward
- New additions bring strategic networks, key introductions and a proven ability to execute
INTERNATIONAL EXPANSION
- HempFusion and Probulin products are planned to be sold across Europe (Ireland & UK)
- Probulin has purchase orders and/or is selling in the Middle East, South Korea, China, Mexico, and India
- Probulin’s Trojan Horse strategy is a gateway to increased international distribution(2)
IPO & STRONG CASH POSITION
- USD $18,315,734 cash as of June 30th
- Second largest cash position in the sector(3)
- No debt
FDA Drug Listed Over the Counter Topicals
We’ve created a unique Over-The-Counter (OTC) drug-listed topical line to provide relief for pain and help reduce the symptoms of eczema and acne. This line includes broad-spectrum hemp extract CBD that harnesses true broad-spectrum power plus a greater diversity of naturally-occurring cannabinoids and other compounds. They work together to support the entourage effect and deliver the most benefits.
Latest News
HempFusion Investor Relations Contact
Spencer MacLean | Tel: 416-803-5638 | Email: [email protected]
(1) Please click here for reference
(2) Leveraging non-CBD products to achieve approved vendor status
(3) Based on available public company presentations and June 30, 2020 Financials